“Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)”, J of Skin, vol. 9, no. 6, p. s612, Nov. 2025, doi: 10.25251/m9gw3y80.